Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 5/20 | 0.38 |
| ▸ | CHRNA6 | Q15825 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13634298 | 0.90 | — | — | |
| SCHEMBL26151483 | 0.82 | EPHX1 (0.36) | GAAKMT2APLA2G1BATG4BALDH1A1 | |
| SCHEMBL31323872 | 0.81 | CHRNB2 (0.41) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL15154826 | 0.79 | GAA (0.48) | GAAKMT2APLA2G1BATG4BALDH1A1 | |
| SCHEMBL11082124 | 0.79 | CHRNB2 (0.40) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14173617 | 0.77 | CHRNB2 (0.56) | GAAKMT2APLA2G1BATG4BALDH1A1 | |
| SCHEMBL21541884 | 0.77 | GAA (0.47) | GAAKMT2APLA2G1BATG4BALDH1A1 | |
| SCHEMBL10406212 | 0.77 | GAA (0.47) | GAAKMT2APLA2G1BATG4BALDH1A1 | |
| SCHEMBL6628756 | 0.77 | CHRNB2 (0.56) | GAAKMT2APLA2G1BATG4BALDH1A1 | |
| SCHEMBL2938449 | 0.77 | PLA2G1B (0.47) | GAAKMT2APLA2G1BATG4BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6888004-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-03 | — | — | US | claimed |
| US-4432985-A | N-alkylated carboxylic acid derivatives as anti-convulsant agents | ABBOTT LABORATORIES (US) | 1984-02-21 | — | — | US | claimed |
| US-7244746-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7238699-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7211669-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-01 | — | — | US | disclosed |
| US-7125990-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| US-6888004-B2 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040254382-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | disclosed |
| US-20040235924-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
| US-20040225130-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-11 | — | — | US | disclosed |
| US-20040225001-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-11 | — | — | US | disclosed |
| EP-1359916-A4 | IMIDAZOLYL DERIVATIVES AS CORTICOTROPIN RELEASING FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1359916-A1 | IMIDAZOLYL DERIVATIVES AS CORTICOTROPIN RELEASING FACTOR INHIBITORS | Bristol-Myers Squibb Company (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20020183375-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-05 | — | — | US | disclosed |
| WO-2002058704-A1 | IMIDAZOLYL DERIVATIVES AS CORTICOTROPIN RELEASING FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| US-4432985-A | N-alkylated carboxylic acid derivatives as anti-convulsant agents | ABBOTT LABORATORIES (US) | 1984-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225001-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | GAA 4134/4885KMT2A 4374/4885PLA2G1B 3678/4885 |
| US-20040225130-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | GAA 4134/4885KMT2A 4374/4885PLA2G1B 3678/4885 |
| US-20020183375-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | GAA 4134/4885KMT2A 4374/4885PLA2G1B 3678/4885 |
| US-20040254382-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | GAA 4134/4885KMT2A 4374/4885PLA2G1B 3678/4885 |
| US-20040235924-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | GAA 4134/4885KMT2A 4374/4885PLA2G1B 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.